Patents by Inventor Nissab Boudjellab

Nissab Boudjellab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
    Patent number: 7737251
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Grant
    Filed: December 23, 2005
    Date of Patent: June 15, 2010
    Assignee: ConjuChem Biotechnologies Inc.
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • LONG LASTING GLUCAGON-LIKE PEPTIDE 2 (GLP-2) FOR THE TREATMENT OF GASTROINTESTINAL DISEASES AND DISORDERS
    Publication number: 20090312259
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Application
    Filed: July 19, 2009
    Publication date: December 17, 2009
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • Long-lasting antiviral fusion inhibitor peptide conjugates comprising albumin and human immunodeficiency virus (HIV) peptides
    Patent number: 7582301
    Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: September 1, 2009
    Assignee: Conjuchem Biotechnologies, Inc.
    Inventors: Dominique P. Bridon, Robert P. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
  • LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION
    Publication number: 20080199483
    Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
    Type: Application
    Filed: October 23, 2007
    Publication date: August 21, 2008
    Applicant: CONJUCHEM BIOTECHNOLOGIES INC.,
    Inventors: Dominique P. Bridon, Robert S. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
  • LONG LASTING FUSION PEPTIDE INHIBITORS OF VIRAL INFECTION
    Publication number: 20080176794
    Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
    Type: Application
    Filed: October 23, 2007
    Publication date: July 24, 2008
    Applicant: CONJUCHEM BIOTECHNOLOGIES INC.
    Inventors: Dominique P. Bridon, Robert S. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
  • Long lasting growth hormone releasing factor derivatives
    Patent number: 7268113
    Abstract: This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.
    Type: Grant
    Filed: February 1, 2002
    Date of Patent: September 11, 2007
    Assignee: ConjuChem Biotechnologies Inc.
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Lucie Jetté, Corinne Benquet
  • Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
    Publication number: 20060217304
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Application
    Filed: December 23, 2005
    Publication date: September 28, 2006
    Inventors: Dominique Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
    Patent number: 7112567
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Grant
    Filed: February 15, 2002
    Date of Patent: September 26, 2006
    Assignee: ConjuChem Inc.
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Léger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • Long lasting fusion peptide inhibitors of viral infection
    Patent number: 7090851
    Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
    Type: Grant
    Filed: September 7, 2000
    Date of Patent: August 15, 2006
    Assignee: ConjuChem Inc.
    Inventors: Dominique P. Bridon, Robert R. Dufresne, Nissab Boudjellab, Martin Robitaille, Peter G. Milner
  • Long lasting fusion peptide inhibitors of viral infection
    Publication number: 20050070475
    Abstract: Peptides exhibiting anti-viral and anti-fusogenic activity are modified to provide greater stability and improved half-life in vivo. The selected peptides include fusion inhibitors DP178 and DP107 and related peptides and analogs thereof. The modified peptides are capable of forming covalent bonds with one or more blood components, preferably a mobile blood component.
    Type: Application
    Filed: September 24, 2004
    Publication date: March 31, 2005
    Applicant: ConjuChem, Inc.
    Inventors: Dominique Bridon, Robert Dufresne, Nissab Boudjellab, Martin Robitaille, Peter Milner
  • Long lasting glucagon-like peptide2(glp-2)for the treatment of gastrointestinal diseases and disorders
    Publication number: 20040248782
    Abstract: This invention relates to glucagon-like peptide 2 (GLP-2) derivatives. In particular, this invention relates to GLP-2 peptide derivatives having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders or diseases such as inflammatory bowel disease and other gastrointestinal functions, from any segment of the gastrointestinal tract, from the oesophagus to the anus.
    Type: Application
    Filed: August 12, 2002
    Publication date: December 9, 2004
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Karen Thibaudeau, Julie Carette
  • Long lasting growth hormone releasing factor derivatives
    Publication number: 20030073630
    Abstract: This invention relates to growth hormone releasing factor (GRF) derivatives. In particular, this invention relates to GRF peptide derivatives having an extended in vivo half-life, for promoting the endogenous production or release of growth hormone in humans and animals.
    Type: Application
    Filed: August 12, 2002
    Publication date: April 17, 2003
    Inventors: Dominique P. Bridon, Nissab Boudjellab, Roger Leger, Martin Robitaille, Lucie Jette, Corinne Benquet
  • Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
    Patent number: 6440417
    Abstract: Antibodies to a therapeutic agent and its derivatives and conjugates are disclosed, including antibodies to argatroban and its derivatives and conjugates. The antibodies are useful as reagents in assays and diagnostic kits for determining the concentration of a therapeutic agent or its derivatives and conjugates in biological samples, and further have therapeutic uses in treatment for potential toxicity associated with stable therapeutic conjugates and derivatives, both in vivo and ex vivo.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: August 27, 2002
    Assignee: ConjuChem, Inc.
    Inventors: Karen Thibaudeau, Dominique Blanchard, Dominique P. Bridon, Alan M. Ezrin, Margaret Hardy, Nissab Boudjellab